Compare KB Financial Group, Inc. (KB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs TransMedics Group Inc — how do they compare? KB Financial Group, Inc. trades at $123.07 (market cap $42.62B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: KB Financial Group, Inc. is far larger — about 15.6× TransMedics Group Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and TransMedics Group Inc for 24 Days on average.
| KB | TMDX | |
|---|---|---|
Market Cap | $42.62B | $2.74B |
Volume | 164,291 | 949,331 |
Sector | Financials | Health |
52-Week High | $132.88 | $150.42 |
52-Week Low | $77.50 | $61.99 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $215.53T | $3.13B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $122.04, down 2.16% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.68, P/B of 0.94, and consistent earnings beats in recent quarters. Revenue grew from $17.77T in 2022 to $21.23T in 2025, with net income rising to $5.83T. Operating cash flow improved significantly to $4.23T in 2025, while analyst consensus shows 33% buy ratings amid positive momentum coverage.
KB presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term consolidation. Key risks include market volatility and execution challenges in non-banking expansion. The stock's current price near support levels and strong institutional interest support a cautiously optimistic outlook for patient investors.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
